close
Business

Investor Awards 9 Million Dollars to Harvard and MIT for Cannabinoids Study

Blog-Cannabis

Harvard Medical School Receives 4,5 Million Dollars For Research

Charles R. Broderick, a former student of Harvard University and MIT, donated to 2 Universities to support basic research on the effects of cannabis on the brain and behavior. The total donation of 9 Million Dollars (4,5 Million Dollars to each facility) is the largest donation to date to support independent research into the science of cannabinoids.

The donation will allow neuroscience and biomedicine experts from Harvard Medical School and MIT to conduct research that could eventually help elucidate the biology of cannabinoids and highlight their effects on the human brain, catalyze treatments and to inform evidence-based clinical guidelines, social policies and evidence-based cannabis regulation.

Lagging behind legislation

With the increasing use of cannabis for medicinal and recreational purposes, there are growing concerns about critical knowledge gaps in the plant.

In 2017, the National Academies of Science, Engineering and Medicine have issued a report asking philanthropic organizations, private companies, government agencies and others to develop a "comprehensive database" of short-term and long-term effects. long-term, beneficial and harmful, of cannabis use.

"Our desire is to fill the void that currently exists in scientific research on cannabis," said Broderick, who was one of the first investors in the Canadian medical market.

Broderick is the founder of Uji Capital, a family office specializing in quantitative opportunities in global equity markets. Identifying the growth of the legal cannabis market in Canada as a strategic investment opportunity, Broderick has taken stakes in Tweed Marijuana and Aphria, which have since become two of the most successful cannabis companies in North America.

Read also Cannabis vs Multiple sclerosis

Subsequently, Broderick made a private investment in Tokyo Smoke, a portfolio of cannabis brands that merged into 2017 to create Hiku Brands, of which he was president. Hiku Brands was acquired by Canopy Growth Corporation in 2018.

Thanks to Broderick's donations to Harvard Medical School, independent studies on neurobiology, its effects on brain development, the therapeutic context, treatment, and its cognitive, behavioral and social implications will be further developed.

"I want to destigmatize the conversation about cannabis - and, in part, that means providing facts to the medical community, as well as to the general public," said Broderick, who argues that independent research should serve as a basis for policy discussions. no matter if it's good for business.

"So we all work from the same information. We need to replace rhetoric with research, "he said.

Harvard Medical School : Mobilizing a community of basic scientists and clinicians to meet a biomedical challenge

The Broderick donation provides 4,5 million to establish the Charles R. Broderick Phytocannabinoid Research Initiative at Harvard Medical School, which will fund basic, translational and clinical research across the HMS community to generate fundamental knowledge about the effects of cannabinoids on brain function, various organ systems and general health.

Read also CBD can counter the negative effects of THC

The research initiative cover the basic sciences and clinical disciplines, ranging from neurobiology and immunology to psychiatry and neurology, taking advantage of the combined expertise of some 30 basic and clinical scientists from the Blavatnik Institute and its affiliated hospitals.

The epicenter of these research efforts will be the Department of Neurobiology under the direction of Bruce Bean and Wade Regehr.

"I am excited about Bob's commitment to the science of cannabinoids," said Dr. Regehr, professor of neurobiology at HMS. "The research efforts made possible by Bob's vision have paved the way for the elucidation of some of the most confusing mysteries of cannabinoids and their effects on the brain and various organ systems."

Cannabinoid compounds activate a variety of brain receptors, and the biological effects downstream of this activation are surprisingly complex, varying with age and sex, and complicated by the physiological state and overall health of the person. This complexity and the high degree of variability in individual biology has hindered scientific understanding of the positive and negative effects of cannabis on the human body.

Tags : schoolÉtudeNeuroscienceSEARCH